Challenges in next generation sequencing of homology recombination repair genomic variants in prostate cancer: A nationwide survey and calibration project in China

Ferlay, 2021, Cancer statistics for the year 2020: An overview, Int J Cancer, 149, 778, 10.1002/ijc.33588 Karantanos, 2013, Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches, Oncogene, 32, 5501, 10.1038/onc.2013.206 Nagaya, 2021, RNA-seq profile of African American men with a clinically localized prostate cancer, Prostate Int, 9, 125, 10.1016/j.prnil.2020.11.002 Lingg, 2022, Meiotic Genes and DNA Double Strand Break Repair in Cancer, Front Genet, 13, 10.3389/fgene.2022.831620 Mateo, 2020, Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial, Lancet Oncol, 21, 162, 10.1016/S1470-2045(19)30684-9 Abida, 2017, Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making, JCO Precis Oncol, 2017 de Bono, 2020, Olaparib for Metastatic Castration-Resistant Prostate Cancer, N Engl J Med, 382, 2091, 10.1056/NEJMoa1911440 Schaeffer, 2021, NCCN Guidelines Insights: Prostate Cancer, Version 1.2021, J Natl Compr Cancer Netw, 19, 134, 10.6004/jnccn.2021.0008 Cornford, 2021, EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer, Eur Urol, 79, 263, 10.1016/j.eururo.2020.09.046 Chen, 2019, Next-generation sequencing in liquid biopsy: cancer screening and early detection, Hum Genom, 13, 34, 10.1186/s40246-019-0220-8 Chung, 2020, Clinical implications of genomic evaluations for prostate cancer risk stratification, screening, and treatment: a narrative review, Prostate Int, 8, 99, 10.1016/j.prnil.2020.09.001 Wallace, 2016, New challenges for BRCA testing: a view from the diagnostic laboratory, Eur J Hum Genet, 24, S10, 10.1038/ejhg.2016.94 de Bono, 2019, 847PD - Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study, Ann Oncol, 30, v328, 10.1093/annonc/mdz248.004 Bronkhorst, 2019, The emerging role of cell-free DNA as a molecular marker for cancer management, Biomol Detect Quantif, 17, 10.1016/j.bdq.2019.100087 Andersson, 2021, Ultrasensitive circulating tumor DNA analysis enables precision medicine: experimental workflow considerations, Expert Rev Mol Diagn, 21, 299, 10.1080/14737159.2021.1889371 Zhang, 2021, Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients, Nat Commun, 12, 11, 10.1038/s41467-020-20162-8 Chi, 2021, Concordance of BRCA1, BRCA2 (BRCA), and ATM mutations identified in matched tumor tissue and circulating tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) screened in the PROfound study, J Clin Oncol, 39, 26, 10.1200/JCO.2021.39.6_suppl.26 Tukachinsky, 2021, Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms, Clin Cancer Res, 27, 3094, 10.1158/1078-0432.CCR-20-4805 Wyatt, 2017, Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer, J Natl Cancer Inst, 109, 10.1093/jnci/djx118 Vandekerkhove, 2019, Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer, Eur Urol, 75, 667, 10.1016/j.eururo.2018.12.042 Volik, 2016, Cell-free DNA (cfDNA): Clinical Significance and Utility in Cancer Shaped By Emerging Technologies, Mol Cancer Res, 14, 898, 10.1158/1541-7786.MCR-16-0044 Richards, 2015, Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, Genet Med, 17, 405, 10.1038/gim.2015.30 Biesecker, 2018, ClinGen Sequence Variant Interpretation Working G. The ACMG/AMP reputable source criteria for the interpretation of sequence variants, Genet Med, 20, 1687, 10.1038/gim.2018.42 Abou Tayoun, 2018, Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion, Hum Mutat, 39, 1517, 10.1002/humu.23626 Brnich, 2019, Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework, Genome Med, 12, 3, 10.1186/s13073-019-0690-2 Li, 2017, Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists, J Mol Diagn, 19, 4, 10.1016/j.jmoldx.2016.10.002 Ballester, 2016, Advances in clinical next-generation sequencing: target enrichment and sequencing technologies, Expert Rev Mol Diagn, 16, 357, 10.1586/14737159.2016.1133298 Zakrzewski, 2019, Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples, BMC Cancer, 19, 396, 10.1186/s12885-019-5584-6 Toland, 2018, Clinical testing of BRCA1 and BRCA2: a worldwide snapshot of technological practices, NPJ Genom Med, 3, 7, 10.1038/s41525-018-0046-7 Chinese Society of, 2021, [Chinese expert consensus on BRCA1/2 variant interpretation(2021 version)], Zhonghua Bing Li Xue Za Zhi, 50, 565 Lindor, 2013, BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management, Oncol, 18, 518, 10.1634/theoncologist.2012-0452 Federici, 2020, Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from breast and ovary cancers, J Exp Clin Cancer Res, 39, 46, 10.1186/s13046-020-01554-6 Fatkin, 2020, Variants of Uncertain Significance and "Missing Pathogenicity", J Am Heart Assoc, 9 Ulz, 2016, Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer, Nat Commun, 7, 10.1038/ncomms12008 Mauger, 2015, Comprehensive evaluation of methods to isolate, quantify, and characterize circulating cell-free DNA from small volumes of plasma, Anal Bioanal Chem, 407, 6873, 10.1007/s00216-015-8846-4